Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (AKRO): 4 pipeline candidates · ~32 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.9 months
D/E 0.05 · 2% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Akero Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$176.0M
Quarterly Burn
$67.2M
Runway
31.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| efruxifermin | Phase 2 |
| efruxifermin (EFX) | Phase 3 |
| EFX | Phase 2 |
| JTE-162 | Phase 1 |
Frequently asked questions
How many drug candidates are in Akero Therapeutics, Inc.'s pipeline?
Akero Therapeutics, Inc. (AKRO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Akero Therapeutics, Inc.'s lead drug candidate?
Akero Therapeutics, Inc.'s most advanced tracked candidate is efruxifermin (Phase 2) for NASH With Fibrosis; NASH/MASH; NASH - Nonalcoholic Steatohepatitis.
What is Akero Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Akero Therapeutics, Inc. has approximately 31.9 months of cash runway.
Who is the CEO of Akero Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Akero Therapeutics, Inc. (AKRO).
Get the full picture on Akero Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.